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Research
AbstrACt
Objective To describe the prevalence of statin utilisation 
by people aged over 50 years in Ireland and the factors 
associated with the likelihood of using a statin, focusing 
particularly on those using statins for primary prevention 
of cardiovascular disease (CVD).
Methods This is a cross-sectional analysis of 
cardiovascular risk and sociodemographic factors 
associated with statin utilisation from wave 1 of The Irish 
Longitudinal Study on Ageing. A hierarchy of indications 
for statin utilisation, consisting of eight mutually 
exclusive levels of CVD-related diagnoses, was created. 
Participants were assigned one level of indication. The 
prevalence of statin utilisation was calculated. The 
likelihood that an individual was using a statin was 
estimated using a multivariable logistic regression model, 
controlling for cardiovascular risk and sociodemographic 
factors.
results In this nationally representative sample (n=5618) 
of community-dwelling participants aged 50 years and 
over, 1715 (30.5%) were taking statins. Of these, 65.0% 
(57.3% of men and 72.7% of women) were doing so for 
the primary prevention of CVD. Thus, almost two-thirds 
of those taking statins did so for primary prevention and 
there was a notable difference between women and men 
in this regard. We also found that statin utilisation was 
highest among those with a prior history of CVD and was 
significantly associated with age (compared with the base 
category 50–64 years; 65–74 years OR 1.38 (95% CI 1.16 
to 1.65); 75+ OR 1.33 (95% CI 1.04 to 1.69)), living with 
a spouse or partner (compared with the base category 
living alone; OR 1.35 (95% CI 1.10 to 1.65)), polypharmacy 
(OR 1.74 (95% CI 1.39 to 2.19)) and frequency of general 
practitioner visits (compared with the base category 0 
visits per year; 1–2 visits OR 2.46 (95% CI 1.80 to 3.35); 
3–4 visits OR 3.24 (95% CI 2.34 to 4.47); 5–6 visits OR 
2.98 (95% CI 2.08 to 4.26); 7+ visits OR 2.51 (95% CI 1.73 
to 3.63)), even after controlling for clinical need. There 
was no association between using statins and gender, 
education, income, social class, health insurance status, 
location or Systematic Coronary Risk Evaluation (SCORE) 
risk in the multivariable analysis.
Conclusion Statin utilisation among those with no history 
of CVD accounted for almost two-thirds of all statin use, in 
part reflecting the high proportion of the population with 
no history of CVD, although utilisation rates were highest 
among those with a history of CVD.
IntrOduCtIOn
background
The last 30 years have seen a large increase 
in the utilisation of statins hydroxy-meth-
ylglutaryl ((HMG)-coenzyme A reductase 
inhibitors) for the primary and secondary 
prevention of cardiovascular disease 
(CVD).1–4 In Ireland, the number of statin 
patient treatment days per 1000 inhabitants 
increased between 2000 and 2003 by 192%, 
the highest recorded increase in a study of 
nine European countries.1 By 2014, over 
€50 million was spent annually in Ireland on 
these medicines in State-funded purchases 
alone.5 While the ageing population in 
high-income countries has been cited as 
a driver of increased utilisation of statins, 
Wallach Kildemoes et al found that increasing 
treatment intensity, rather than population 
ageing, was almost exclusively responsible for 
this rise.6 
strengths and limitations of this study
 ► Large, nationally representative sample of 
community dwelling adults with self-reported 
verified drug utilisation.
 ► Good agreement between self-reported prescription 
medication use and pharmacy dispensing records 
for this cohort has been reported.
 ► Breakdown of utilisation according to a hierarchy of 
diagnoses enabled analysis of primary/secondary 
prevention use.
 ► Self-reported doctor diagnoses and recall of general  
practitioner visits may be subject to recall bias.
 ► Some diagnostic criteria, previous SCORE results and 
discontinuation of statins could not be ascertained.
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Statins may be prescribed for those with known CVD 
(secondary prevention), diabetes and familial hypercho-
lesterolaemia (primary prevention), as well as for those 
considered ‘at risk’ of CVD but who have not yet had an 
event (primary prevention). The clinical guidelines rele-
vant to the cohort in this study were those of the European 
Society of Cardiology 2007,7 which recommended that 
those with established CVD and diabetes be considered 
as the highest risk group. All others were to be assessed 
using the SCORE risk assessment tool.8 If a person was 
found to be above a 5% risk threshold (over 10 years) 
using this method, or if they had established CVD or 
diabetes, the total cholesterol (TC) level recommended 
was 4.5 mmol/L and/or a low-density lipoprotein (LDL) 
level of 2.5 mmol/L.
There is some evidence that statins are underused in 
certain sections of the population9–12 and that statins are 
not targeted at those most likely to benefit.13 14 However, 
increases in statin prescribing may be linked to changing 
clinical guidelines, which have been identified as drivers 
of a process of medicalisation as they generally widen 
the definition of disease.15 Updates of guidelines have 
included changes to thresholds of blood cholesterol levels 
and to risk categorisation, which lead to recommenda-
tions for statin therapy to expanded numbers of people. 
In particular, the use of statins in people without previous 
CVD (primary prevention) has been the subject of 
controversy.16 17 Some authors criticise the extrapolation 
of clinical guidelines to subgroups, such as women or the 
elderly,18 and those with diabetes,19 where the evidence 
of a favourable risk-benefit ratio may not be conclusive. 
Although some studies have analysed statin use by broad 
diagnostic groupings,4 14 20 analysis by diagnostic indica-
tion,6 as well as by ‘at-risk’ categorisation, could increase 
knowledge of drug utilisation patterns. This, in turn, 
could help explain the drivers of increased utilisation and 
the extent to which statins are used in patients with lower 
CVD risk, where the benefits may be limited or where the 
harms of statins may outweigh those benefits, particularly 
in primary prevention of CVD.17 21 22
Wallach Kildemoes et al 6 constructed a hierarchy of 
indications for which statins were prescribed (see online 
supplementary appendix 1, table A1). This hierarchy was 
based on european guidelines on the prevention of CVD,23 
the most recent of which, at the time of data collection, 
were published in 2007. This consisted of eight mutually 
exclusive levels of markers of CVD-related diagnoses and 
diabetes. The indication for a person with several of the 
listed medical conditions was considered to be that which 
placed them highest on the hierarchy. For example, if a 
person had both a previous myocardial infarction (MI) 
and hypertension, they were stratified into the MI cate-
gory, that being the higher-level indication.
Objective
The aim of this study was to describe the prevalence of 
statin utilisation by indication, age and gender, in commu-
nity-dwelling adults in Ireland aged 50 years and older in 
the period 2009–2011, with a focus on primary prevention 
of CVD. This included an examination of those factors, in 
particular CVD-related diagnoses based on a hierarchy of 
indications, which are associated with increased statin util-
isation. A secondary analysis was undertaken to examine 
statin utilisation based on the risk of developing CVD, as 
measured by the SCORE risk assessment tool.
MethOds
design
The study used cross-sectional data from wave 1 (2009–
2011) of The Irish Longitudinal Study on Ageing 
(TILDA). TILDA collects data on a nationally represen-
tative sample of community living adults aged 50 years 
and older in Ireland.24 This allowed us to examine self-re-
ported drug utilisation rather than prescribing data, 
which may be a more accurate way of assessing drug use. 
Ethical approval for the TILDA study was received from 
the Trinity College Research Ethics Committee and all 
participants provided written informed consent. As our 
study comprised secondary analysis of TILDA data, which 
is anonymised, further participant consent or ethical 
approval was not required.
Participants and setting
Participants were selected using RAMSAM, a system for 
drawing a random sample from the Irish geodirectory.25 
Participants took part in a face-to-face computer-aided 
personal interview (CAPI) in their home, followed by a 
health assessment either in their home or at a designated 
health centre. Figure 1 shows the flow chart of partici-
pants included in our analysis. Of the 8175 individuals 
within TILDA aged over 50 years, 5634 undertook a 
health assessment. Since diagnosis of familial hypercho-
lesterolaemia was not clear from our data, we removed 16 
Figure 1 Flow chart of the number of participants included 
in the analysis. LDL, low-density lipoprotein. Source: Analysis 
of The Irish Longitudinal Study on Ageing (TILDA) wave 1 
data.
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individuals whose LDL levels were >6 mmol/L from the 
sample. This gave a final sample of 5618 individuals.
Variables
A full description of the variables used is presented in 
online supplementary appendix 2, table A2.1.
Statin use
Current medication use was recorded directly from 
respondents and was cross-checked by the interviewer 
who examined medication labels, which the participant 
showed them. Good agreement between self-reported 
prescription medication use and pharmacy dispensing 
records for this cohort has been reported.26
Sociodemographic variables
Sociodemographic data were collected by TILDA 
including age, gender and living arrangement. Six cate-
gories of both socioeconomic status and income levels 
were described. Educational status was described as 
‘primary or none’, ‘secondary’ or ‘third level or higher’. 
Participants were described as living either in Dublin city 
or environs, in another urban area or in a rural area.
Healthcare variables
Medical insurance status was described as ‘no cover’, 
‘medical insurance’ for those with private medical insur-
ance or ‘medical card’ for those whose medical costs were 
covered by the State. We recoded the number of GP visits 
into five categories—none, 1–2, 3–4, 5–6 and 7 or more. 
Polypharmacy was recorded in the data as receiving five 
or more medications (excluding supplements) simultane-
ously. For the purpose of our analysis, we did not include 
statins as one of the five medications.
Indication
The indication for statin usage was determined during 
the CAPI. Participants were asked: "Has a doctor ever told 
you that you have any of the following conditions?" The condi-
tions listed included: high blood pressure or hyperten-
sion; angina; a heart attack; congestive heart failure; 
diabetes or high blood sugar; a stroke; ministroke or tran-
sient ischaemic attack; high cholesterol; a heart murmur 
or any other heart trouble. An indication hierarchy was 
used as described by Wallach Kildemoes et al and partici-
pants were assigned to the highest level of indication. The 
categories included in the hierarchy were MI, ischaemic 
heart disease (IHD), stroke, potential artherosclerotic 
conditions (PAC), diabetes, hypertension, high choles-
terol and none of these conditions (no diagnosis).
Analysis
The prevalence of statin utilisation was calculated overall 
and for each age, gender and indication. A multivari-
able logistic regression model of whether an individual 
was taking a statin or not was estimated, controlling for 
cardiovascular indication and sociodemographic factors. 
This provides, for each covariate, the odds of statin use 
for one category of the covariate relative to another 
category, adjusting for all other covariates in the model. 
In particular, we estimated a stepwise (backward selec-
tion) model and applied a 10% significance level for 
removal. This means that we removed the variable with 
the greatest P value, one at a time, until all remaining 
variables had a P value <10% threshold. The choice of 
variables included in the initial model was influenced by 
the data available in TILDA, as well as previous research, 
some of which had found significant associations between 
statin use and educational status,27 gender,14 20 27 age,4 28 
socioeconomic status,10 20 28 number of GP visits,10 poly-
pharmacy29 30 and indication.10 14 Other research found 
non-significant associations between statin use and marital 
status.27 Survey weights supplied by TILDA were applied 
to reduce non-response bias. The derivation of these 
weights is described in online supplementary appendix 2. 
The characteristics used for calibration were age, sex and 
education, sourced from the Quarterly National House-
hold Survey 2010 compiled by the Irish Central Statistics 
Office.31 Maximum missing data were <1%.
The SCORE tool was used to assess 10-year risk of a 
fatal CVD event in participants without established CVD 
or diabetes aged 50–64 years, stratified as either above 
or below a 5% risk threshold.8 A multivariable logistic 
regression model was also used to examine how statin 
utilisation related to SCORE risk, controlling for cardio-
vascular indication, healthcare utilisation and sociodemo-
graphic factors.
The statistical software Stata/MP V.13.1 was used to 
conduct the analyses.
results
The characteristics of the sample are described in table 1.
Prevalence according to age and gender
Table 2 shows descriptive analyses for prevalence by indi-
cation and age. Within this sample of 5618 people, 30.5% 
were currently taking statins. Online supplementary 
appendix 2, tables A2.2, A2.3 show corresponding data 
for females and males, respectively, showing that higher 
proportions of men (32.5%) than women (28.8%) take 
statins (the 95% CIs for these groups do not overlap). 
Table 2 also shows the prevalence of statin use in each 
age category for our sample. Statin utilisation increased 
monotonically with age; 22.6% of those aged 50–64 years, 
41.1% of those aged 65–74 years and 45.6% for those 
aged 75 years or more. The increased use of statins with 
increasing age was observed in each gender category 
(see supplementary appendix 2, tables A2.2, A2.3), with 
lower proportions of women than men taking statins in 
each age category.
Prevalence according to indication
Table 2 shows, for example, that of the 250 people who 
have had MI, 185 are taking statins. This means that 74% 
of those who have had MI take statins. As the proportion 
of people who have had MI is low in the population, this 
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represents 10.9% of statin users. On the other hand, a 
smaller proportion of those with ‘high cholesterol’ take 
statins (44.1%), but as they represent a larger propor-
tion of the population, this accounts for 24.5% of all 
statin users. The results clearly show high, although not 
universal, uptake rates of statins for those with estab-
lished CVD (eg, 74.0% for MI and 73.7% for IHD), with 
lower, but still highly significant uptake rates for primary 
prevention (eg, 34.8% for hypertension and 44.1% for 
high cholesterol).
Those with established CVD (ie, MI, IHD, stroke and 
PAC) accounted for 34.9% of those taking statins, while 
those with diabetes accounted for 9.4% (table 2). There-
fore, overall, those without established CVD or diabetes 
accounted for 55.7% of those taking statins. However, 
of all women taking statins, 64.7% did not have CVD or 
diabetes compared with 46.2% of men (see online supple-
mentary appendix 2, tables A2.2, A2.3). Overall, 65.0% of 
statin users did not have a history of established CVD and 
were taking statins for primary prevention. The propor-
tion of men taking statins without a history of CVD was 
57.3%, while the corresponding proportion for women 
was 72.7%. These high proportions reflect, in part, the 
greater proportions of the cohort with no history of CVD.
Factors associated with statin utilisation
Table 3 presents the estimated ORs obtained for each 
variable included in the final multivariable logistic regres-
sion model, adjusting for all other variables in the model.
Overall, those aged 65–74 years were more likely to 
be prescribed a statin than those aged 50–64 years (OR 
1.38; 95% CI 1.16 to 1.65), as were those in the oldest age 
bracket, 75 and over (OR 1.33; 95% CI 1.04 to 1.69).
The number of times a person reported visiting a GP 
in the previous year was predictive of the likelihood of 
taking a statin relative to those who had not reported 
visiting a GP in the previous year (table 3). Polypharmacy, 
defined as taking five or more medications, was also 
strongly predictive of statin utilisation (OR 1.74; 95% CI 
1.39 to 2.19). People who were living with a spouse or 
partner were more likely than those living alone to be 
taking a statin (OR 1.35; 95% CI 1.10 to 1.65). The odds 
of taking statins for those with a diagnosis of MI was, as 
expected, relatively high compared with those without 
MI. All indications were statistically significant except for 
the IHD category.
The ORs for socioeconomic variables such as income, 
social class and education level were not found to be 
statistically significant, nor were ORs for gender, health 
insurance status or whether the person lived in a rural or 
urban area.
sCOre analysis
SCORE risk was calculated in those 
without CVD or diabetes whose LDL 
and/or TC levels were above the recommended thresh-
olds (n=3551). Eighteen per cent of those whose SCORE 
result was ≥5% were taking statins; 17% of those with a 
Table 1 Sample descriptive statistics (n=5618)
Variable Categories %
Statins Yes 30.2
No 69.8
Age (years) 50–64 60.3
65–74 26.5
75+ 13.2
Sex Female 53.6
Male 46.4
Education Primary/none 25.6
Secondary 41.3
Third level/higher 33.1
Income (per annum) <€10 000 9.8
≥ €10 000, < €20 000 18.7
≥ €20 000, < €40 000 34.2
≥ €40 000, < €70 000 20.3
≥ €70 000, < €2 000 000  8.8
Missing 8.2
Social class Professional, managerial and 
technical workers
24.9
Non-manual and skilled manual 
workers
21.0
Semi-skilled and unskilled  
workers
11.6
Farmers 5.7
Not applicable 26.3
Unknown and refused 10.6
Insurance No cover 10.4
Medical insurance 43.6
Medical card 46.0
General practitioner 
visits
0 12.6
1–2 36.9
3–4 26.6
5–6 11.5
7+ 12.4
Polypharmacy No 80.0
Yes 20.0
Lives with Living alone 60.3
Living with spouse/partner 26.5
Living with others 13.2
Location Dublin city or town 26.3
Another town or city 27.3
Rural area 46.5
Indication Myocardial infarction 4.5
Ischaemic heart disease 3.2
Stroke 2.7
Potential atherosclerotic conditions 8.7
Diabetes 5.0
Hypertension 23.0
High cholesterol 17.0
No cardiovascular disease-related 
diagnosis
36.0
Source: Analysis of The Irish Longitudinal Study on Ageing wave 1 data.
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SCORE of <5% were taking statins (results not shown). 
However, it was not possible to interpret whether their 
SCORE risk level had been altered by statin utilisation 
nor could we ascertain what proportion in either risk 
group had potentially discontinued statins previously 
used.
In a separate multivariable model using the subsa-
mple of those without CVD or diabetes whose LDL and/
or TC levels were above the recommended thresholds, 
the SCORE risk category was not found to be statisti-
cally significantly related to taking a statin (results not 
presented).
dIsCussIOn
Key results
We found that almost one-third of adults over 50 in this 
Irish cohort were taking statins. Almost two-thirds of these 
took statins for the primary prevention of CVD, but there 
was a notable difference between men and women. Almost 
three-quarters of women taking statins were doing so for 
primary prevention, compared with just over half of men. 
Prevalence of statin utilisation was found to increase with 
age.
Diagnostic indication was a predictor for increased like-
lihood of taking statins, with those with a history of MI, as 
expected, having the highest prevalence of statin utilisation. 
However, although the indication hierarchy used implied 
an ordering of indications corresponding to priorities for 
statin treatment, the likelihood of utilising a statin did not 
uniformly follow this order. Both the diagnoses ‘diabetes’ 
and ‘high cholesterol’ were found to have higher odds than 
warranted according to the hierarchy. However, it should 
be noted that this may be due to the numbers being small 
in some indication categories, leading to wide CIs, and thus 
the disparity in ordering should not be overinterpreted. 
Polypharmacy, frequency of GP visits and living arrange-
ments were also significantly associated with the likelihood 
of taking a statin, while controlling for all other variables in 
the model.
The 2007 European Society of Cardiology clinical guide-
lines recommended that those with a SCORE of over 5% 
be considered for statin treatment.7 28 This study found that 
less than a quarter of those above this threshold were using 
statins, as were one-fifth of those below. This may indicate 
that GPs or some other doctors initiating statin therapy do 
not use SCORE to risk assess their patients, but due to the 
limitations of our data it is difficult to interpret if this is the 
case.32 A recent UK study of a primary care database found 
that most patients initiated on statins did not have a risk 
score recorded. While statins were initiated in 27.5% of 
clinical encounters and a risk score was recorded in 80% 
of all encounters, only 7.5% of encounters recorded both a 
risk score and subsequent statin initiation.33
strengths and limitations
A strength of our analysis was that it was conducted on 
a large, nationally representative sample of communi-
ty-dwelling adults, aged over 50 years in Ireland. Recording 
medication use directly from respondents with verification 
allows a closer examination of real-life usage compared with 
dispensing data that may not account for some elements 
of non-adherence. Survey weights were applied in the 
multivariable analysis to reduce potential bias from non-re-
sponse in the TILDA data collection. This means that our 
findings are therefore more likely to be representative. 
These factors will allow for the generalisation of our find-
ings to community living adults aged 50 years and over in 
Ireland. Our study will therefore be useful for cross-country 
comparisons of statin utilisation, as well as the patterns by 
which these drugs are prescribed. The breakdown of util-
isation according to indication will inform the debate on 
Table 3 Adjusted ORs of statin use from multivariable 
logistic regression model
OR P value 95% CI
Age (years) 
  50–64 (base) 1.00 – – 
  65–74 1.38 <0.000 1.16 to 1.65
  75+ 1.33 0.022 1.04 to 1.69
GP visits 
  0 (base) 1.00 – – 
  1–2 2.46 <0.000 1.80 to 3.35
  3–4 3.24 <0.000 2.34 to 4.47
  5–6 2.98 <0.000 2.08 to 4.26
  7+ 2.51 <0.000 1.73 to 3.63
Polypharmacy 
  No 1.00 – – 
  Yes 1.74 <0.000 1.39 to 2.19
Lives 
  Alone (base) 1.00 – – 
  With spouse/partner 1.35 0.004 1.10 to 1.65
  With other 0.95 0.640 0.76 to 1.18
Indication 
  MI (base) 1.00 – – 
  IHD 0.98 0.948 0.59 to 1.64
  Stroke 0.51 0.009 0.31 to 0.84
  PAC 0.25 <0.000 0.17 to 0.36
  Diabetes 0.50 0.002 0.33 to 0.77
  Hypertension 0.21 <0.000 0.15 to 0.31
  High cholesterol 0.44 <0.000 0.31 to 0.64
  None of above 0.03 <0.000 0.02 to 0.04
Observations 5528 
Pseudo-R2 0.2474 
The model is a stepwise (backward selection) multivariable binary 
logistic model, applying a 10% significance level for removal. This 
means that only variables found to be statistically significant at the 
10% level are included in the final model.
IHD, ischaemic heart disease; MI, myocardial infarction; PAC, 
potential atherosclerotic conditions; TILDA, Analysis of The Irish 
Longitudinal Study on Ageing.
Source: TILDA wave 1 data.
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the appropriateness of statin prescribing in subgroups of 
gender and age, diagnostic indications and those who fall 
into the primary and secondary prevention categories.
The study is limited in that it relies on self-reported 
doctor diagnoses and recall of the number of GP visits, 
which may be subject to recall bias. When constructing our 
indication hierarchy, the reported diagnosis of ‘any other 
heart trouble’ could not be used and so we may have under-
estimated the prevalence of those within the secondary 
prevention category. The diagnostic category ‘potential 
atherosclerotic conditions’ may include diagnoses that are 
not atherosclerotic in origin. Also, the diagnostic category 
‘peripheral arterial disease’ could not be ascertained due 
to limitations of the data gathered in TILDA. We have no 
information on those who have declined or discontinued 
statins and it is known that poor adherence to statins is 
common.28 We could not distinguish those with type I and 
type II diabetes. This is relevant as the 2007 guidelines 
distinguish between these groups.23 However, numbers of 
people with type 1 diabetes are relatively small compared 
with those with type 2 in the age group over 50 years. 
Although diagnosis of familial hypercholesterolaemia was 
not clear in the data, we removed those whose LDL levels 
were >6 mmol/L from the sample. As this comprised 16 
people this would not have affected results. Finally, it should 
be noted that given the cross-sectional nature of our data 
and the possibility of residual confounding, the results from 
our multivariable analysis should be considered as statistical 
associations rather than causal effects.
Interpretation
Primary and secondary prevention
While there is higher prescribing of statins for those with 
established CVD as would be expected, our finding that a 
large proportion of statins are used for the primary preven-
tion of CVD is in line with international findings that the 
distribution of statin prescribing has shifted towards those 
at the lower end of the indication hierarchy.3 34
Previous Irish research, using a subsample of TILDA data 
(aged 50–64 years), found that despite clinical guidelines 
recommending the use of statins in those with CVD or 
diabetes, treatment prevalence was considered low in these 
groups, at 69% and 57%, respectively.9 In addition, this 
previous study found a low level of treatment prevalence 
in those without CVD and diabetes, but whose SCORE 
was ≥5%. Both findings are in line with the current study. 
However, by stratifying participants into the indication hier-
archy, our study allowed those in the ‘primary prevention’ 
group to be analysed in greater detail.
Overall, 28.8% of women and 32.5% of men in our cohort 
were taking statins. We found that the majority (65.0%) of 
our cohort was utilising statins for primary prevention of 
CVD, with a notable difference between men (57.3%) and 
women (72.7%).
Age
Our study showed that the odds of statin usage were higher 
at older age groups compared with the base category aged 
50–64  years. This was similar to findings in Denmark,18 New 
Zealand28 and the UK,10 14 except that a decrease in utili-
sation was found in these studies in the oldest age groups.
Socioeconomic factors
In line with a previous Irish study,9 we did not find educa-
tion level, social class, income or whether the person had 
medical insurance or a medical card to be statistically signif-
icant predictors of statin usage. An exception was found in 
the previous study for those at high SCORE risk, who were 
twice as likely to be taking statins if eligible for a medical 
card.
Conflicting findings about statin utilisation and socio-
conomic factors have been reported in studies from other 
countries.4 10 11 20 27 28 These differences may be a result of 
differences in access and entitlements within health systems, 
as well as differing social, political and cultural contexts.35 
Countries may vary in reimbursement regulation,1 27 28 type 
of insurance cover (such as Medicaid, Medicare and private 
insurance in the USA),11 clinical guideline recommenda-
tions,14 local medical and patient culture as well as differ-
ences in demand from patients in differing socioeconomic 
groups.1 28
Number of GP visits
Controlling for indication, a person was more likely to be 
using a statin if they had visited their GP in the previous 
year than if they had not. The estimated OR increased with 
number of GP visits until three to four visits and decreased 
thereafter, although there was considerable overlap in the 
95% CIs for different frequencies of GP visits. In their study 
of factors influencing the prescribing of statins in the UK, 
Wu et al 10 found that statin prescribing increased with 
number of blood pressure measurements, a proxy for GP 
visits and perception of CVD risk. However, the highest 
number of GP visits described was four or more and their 
study may have shown a similar pattern to ours were the 
number of visits stratified in a similar manner.
Polypharmacy
Polypharmacy, commonly defined as the use of five 
or more regular medicines, was found to be a strong 
predictor of statin prescription. In other words, 
controlling for clinical indication, a person receiving 
five or more medicines (excluding statins) was more 
likely to be taking a statin. A recent Irish study found 
that the prevalence of polypharmacy in those over 
65 years in 2012 was 60%,36 and that statins were the 
drug category prescribed to the highest number of 
individuals. Another study reported that lipid-mod-
ifying drugs were the most commonly reported medi-
cation class (69%), along with antithrombolytics, used 
by those reporting polypharmacy.37 Our finding raises 
questions as to why, controlling for diagnostic indica-
tion, someone receiving five or more medicines would 
be more likely to receive a statin. This could be based 
on differences in patient preferences as well as chal-
lenges to following clinical guidelines for patients with 
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multimorbidity, which is closely linked with polyphar-
macy.38 Some studies have found an association between 
polypharmacy and increased likelihood of statin use29 30 
and adherence to statins,39 40 while others found that 
people subject to polypharmacy were less likely to 
adhere to medicines, including statins.41 Further quali-
tative research is recommended to explore this finding.
Indication hierarchy
The indication hierarchy implied an ordering of indi-
cations6 corresponding to priorities described in Euro-
pean guidelines.23 However, our analysis showed that 
the likelihood of using a statin did not exactly follow 
this order of prescribing priority. Both ‘high choles-
terol’ and ‘diabetes’ were found to have higher odds 
than warranted according to the hierarchy, although 
again we acknowledge the caveat that this may be due 
to small numbers for some indication categories. Those 
with high cholesterol were more likely to receive statins 
than those with PAC and hypertension, whereas those 
with SCOREs over the recommended risk threshold 
had low levels of statin utilisation. This could imply an 
overemphasis on high cholesterol, a single risk factor, 
as a reason to prescribe rather than prescribing based 
on overall risk assessment. This finding corresponds 
with those from the USA,14 Norway,27 the UK10 and 
Australia.42
In our study, 57.8% of people with diabetes were 
taking statins and they accounted for 9.4% of preva-
lent statin users. This finding was similar to previous 
Irish9 and Danish findings.22 Two US studies found that 
48%10 of ‘eligible diabetics’ and 52%14 of people with 
both diabetes and hyperlipidaemia were taking statins. 
In those without a diagnosis of hyperlipidaemia, this fell 
to 12%.
COnClusIOn
This study describes statin utilisation in a representative 
sample of people aged over 50 years in Ireland. We show 
high, although not universal, uptake rates of statins for 
those with established CVD, with lower, but still highly 
significant uptake rates for primary prevention. Given 
the ongoing debate on the appropriateness of statin use 
in primary prevention,22 43 44 it is significant that such 
a large proportion of Irish users fall into this category, 
particularly women. In addition, the possible focus on 
hyperlipidaemia as a reason for prescribing instead of 
overall CVD risk may indicate an overemphasis on this 
single risk factor.14 42 Polypharmacy, controlling for 
indication, was strongly associated with statin use. This 
finding warrants further investigation.
Statins are widely prescribed and command a large 
share of drug expenditure in Ireland and other countries. 
An increasingly larger proportion of the population are 
using statins, and this is becoming very resource intensive 
and arguably unsustainable. The evidence base for statin 
use in various diagnostic categories varies19 22 and thus, 
the benefit-to-risk ratios for each also vary. There have 
been concerns about the medicalisation of risk factors 
such as mild hypercholesterolaemia.45 Various commen-
tators have pointed out that the benefits of prescribing a 
medicine must outweigh the harms46 and that the budget 
impact of thresholds for treatment needs to be consid-
ered.47 However, uncertainties abound when deciding on 
cost-effective treatment thresholds.48 49 It would therefore 
seem appropriate to consider whether widespread use of 
statins in some of these diagnostic categories represents 
the best use of scarce resources, particularly in low-risk 
groups.50
The debate on the appropriate use of statins for primary 
prevention of CVD is ongoing and highly topical.17 43 51–54 
At the heart of this debate is the question as to whether the 
benefits of taking statins outweigh the harms and costs for 
patients in the primary prevention category. The first step 
towards answering this question is to consider current utilisa-
tion and indication for use, as we have done, which provide 
important contextual information for the debate on statin 
use.
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